Syndeio Biosciences

Syndeio Biosciences is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in central nervous system disorders. The company's proprietary Boost™ Synapse Pharmacology Platform integrates electrophysiology, behavioral assays, and human neuronal network testing to predict clinical outcomes with unprecedented accuracy. Initially developed at Stanford University, Boost™ is now being expanded through proprietary IP and data systems to reduce the risk of new synaptic drugs and guide effective treatment strategies. Syndeio's clinical pipeline includes its lead asset zelquistinel, currently in Phase 2 development for major depressive disorder, which will soon enter the industry’s first Alzheimer’s disease biomarker study, as well as apimostinel, which is currently in an investigator-led Phase 2 study for acute depression. The company is headquartered in Indianapolis, with research laboratories in Menlo Park, California, and Evanston, Illinois, focusing on advancing the Boost™ Synapse Pharmacology Platform.